- Home
- SOLV vs NBIX Comparison
SOLV vs NBIX Comparison
Compare SOLV & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOLV
- NBIX
- Stock Information
- Founded
- SOLV 2023
- NBIX 1992
- Country
- SOLV United States
- NBIX United States
- Employees
- SOLV N/A
- NBIX N/A
- Industry
- SOLV
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOLV
- NBIX Health Care
- Exchange
- SOLV NYSE
- NBIX Nasdaq
- Market Cap
- SOLV 12.6B
- NBIX 11.8B
- IPO Year
- SOLV N/A
- NBIX 1996
- Fundamental
- Price
- SOLV $67.52
- NBIX $117.44
- Analyst Decision
- SOLV Hold
- NBIX Buy
- Analyst Count
- SOLV 9
- NBIX 24
- Target Price
- SOLV $68.00
- NBIX $163.91
- AVG Volume (30 Days)
- SOLV 1.1M
- NBIX 1.0M
- Earning Date
- SOLV 11-26-2024
- NBIX 10-30-2024
- Dividend Yield
- SOLV N/A
- NBIX N/A
- EPS Growth
- SOLV N/A
- NBIX 97.40
- EPS
- SOLV 4.16
- NBIX 3.73
- Revenue
- SOLV $8,215,000,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- SOLV $2.17
- NBIX $26.97
- Revenue Next Year
- SOLV $0.30
- NBIX $16.69
- P/E Ratio
- SOLV $16.21
- NBIX $31.50
- Revenue Growth
- SOLV 0.60
- NBIX 25.72
- 52 Week Low
- SOLV $47.16
- NBIX $108.14
- 52 Week High
- SOLV $77.17
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- SOLV N/A
- NBIX 42.69
- Support Level
- SOLV N/A
- NBIX $119.08
- Resistance Level
- SOLV N/A
- NBIX $129.67
- Average True Range (ATR)
- SOLV 0.00
- NBIX 3.34
- MACD
- SOLV 0.00
- NBIX -0.02
- Stochastic Oscillator
- SOLV 0.00
- NBIX 14.59
About SOLV SOLVENTUM CORP
Solventum Corp is an independent healthcare company with a primary focus on addressing healthcare challenges. Its diverse product portfolio spans the healthcare industry, including medical solutions, oral care, health information systems, and separation and purification sciences.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.